Case report: Neonatal delayed peristalsis after in-utero exposure to clozapine;Occlusion digestive néonatale fonctionnelle et transitoire après exposition in utero à la clozapine (Leponex®): À propos d'un cas

Archives de Pediatrie

Volumn 19, Issue 9, 2012, Pages 913-916

  Moreno Bruna, M D ^a   de Montgolfier, I ^b   Chabaud, M ^b   Dommergues, M ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b ARMAND TROUSSEAU HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE;

ARTICLE; CASE REPORT; CLINICAL FEATURE; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; MALE; MEDICAL HISTORY; NEWBORN; PATIENT MONITORING; PERISTALSIS;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; INFANT, NEWBORN; INTESTINAL OBSTRUCTION; MALE; PERISTALSIS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; SCHIZOPHRENIA;

EID: 84865395357     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/j.arcped.2012.06.019     Document Type: Article

References (14)

1. McKenna K., Koren G., Tetelbaum M., et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005, 66:444-449. [quiz 546].
2. Gupta N., Grover S. Safety of clozapine in 2 successive pregnancies. Can J Psychiatry 2004, 49:863.
3. Iqbal M.M., Rahman A., Husain Z., et al. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 2003, 15:33-48.
4. Palmer S.E., McLean R.M., Ellis P.M., et al. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 2008, 69:759-768.
5. Mamelle N., Munoz F., Grandjean H. Croissance fœtale à partir de l'étude AUDIPOG. I. établissement de courbes de référence. J Gynecol Obstet Biol Reprod (Paris) 1996, 25:61-70.
6. Carmichael S., Abrams B., Selvin S. The pattern of maternal weight gain in women with good pregnancy outcomes. Am J Public Health 1997, 87:1984-1988.
7. Newham J.J., Thomas S.H., MacRitchie K., et al. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry 2008, 192:333-337.
8. Begaud B., Evreux J.C., Jouglard J., et al. Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Therapie 1985, 40:111-118.
9. Peyriere H., Roux C., Ferard C., et al. Antipsychotics-induced ischaemic colitis and gastrointestinal necrosis: a review of the French pharmacovigilance database. Pharmacoepidemiol Drug Saf 2009, 18:948-955.
10. Falterman C.G., Richardson C.J. Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr 1980, 97:308-310.
11. Meut C., Bavoux F., Cynober E., et al. Necrotizing enterocolitis in a newborn: maternal psychotropic drugs suspected. Can J Psychiatry 1994, 39:127.
12. Novikova N., Chitnis M., Linder V., et al. Atypical antipsychotic (clozapine) self-poisoning in late pregnancy presenting with absent fetal heart rate variability without acidosis and delayed peristalsis in the newborn baby: a case report. Aust N Z J Obstet Gynaecol 2009, 49:442-444.
13. Barnas C., Bergant A., Hummer M., et al. Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk. Am J Psychiatry 1994, 151:945.
14. Jaquenoud Sirot E., Knezevic B., Morena G.P., et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 2009, 29:319-326.